Michael J. Kadan

Biomed Research Institute — United States

Medicine · Health Sciences

12h-index1.1kcitations24works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(10), Virus-based gene therapy research(8), CRISPR and Genetic Engineering(6), Viral Infectious Diseases and Gene Expression in Insects(6), Biosimilars and Bioanalytical Methods(4)

Publications24 total

Rethinking lentiviral manufacturing for cell and gene therapies: from platform design to point-of-care delivery
Cell and Gene Therapy Insights·2025Open Access
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial
EClinicalMedicine·2025· 2 citedOpen Access
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Nature Communications·2021· 67 citedOpen Access
Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain
Blood·2021
CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity
Blood·2020· 14 cited
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nature Medicine·2020· 439 cited
On Site Manufacture of AntiCD19 CAR-T Cells. Responses in Subjects with Rapidly Progressive Refractory Lymphomas.
Biology of Blood and Marrow Transplantation·2020· 2 citedOpen Access
Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy
Biology of Blood and Marrow Transplantation·2020· 13 citedOpen Access
Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas
Blood·2019· 3 cited
Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.
Journal of Clinical Oncology·2019· 3 cited
<i>In Vivo</i> Ligand-Inducible Regulation of Gene Expression in a Gutless Adenoviral Vector System
Human Gene Therapy·2003· 12 cited
Intraocular expression of endostatin reduces VEGF‐induced retinal vascular permeability, neovascularization, and retinal detachment
The FASEB Journal·2003· 130 cited
Optimization of the Generation and Propagation of Gutless Adenoviral Vectors
Human Gene Therapy·2003· 73 cited
Generation and Characterization of E1/E2a/E3/E4-Deficient Adenoviral Vectors Encoding Human Factor VIII
Molecular Therapy·2001· 66 citedOpen Access
A Versatile Framework for the Design of Ligand-Dependent, Transgene-Specific Transcription Factors
Molecular Therapy·2001· 23 citedOpen Access
Evaluation of Adenoviral Vectors by Flow Cytometry
Methods·2000· 35 cited
Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy
Blood·1998· 106 citedOpen Access
Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy
Blood·1998· 12 citedOpen Access
Factors Affecting Retroviral Vector Function and Structural Integrity
Virology·1993· 85 cited
Correlation of <sup>125</sup>I‐LSD autoradiographic labeling with serotonin voltage clamp responses in <i>Aplysia</i> neurons
Synapse·1991· 4 cited
page 1 of 2Next →

Frequent Co-authors

Boro Dropulić(10), Rimas J. Orentas(9), Dina Schneider(8), Paolo F. Caimi(8), Folashade Otegbeye(8), Rafick‐Pierre Sékaly(8), Andrew Worden(7), David N. Wald(7), Jane Reese(7), Michael Kaleko(6), Sheila Connelly(6), Ashish Sharma(6), Marcos de Lima(6), Kirsten M Boughan(6), Molly Gallogly(6), Leland Metheny(6), Benjamin Tomlinson(6), Matthew Cooper(5), Dawn B. Kayda(4), Winfried Krüger(4)